Multi-Jurisdiction Health Technology Assessment Evidence Synthesis

Role: Senior Director of Global Market Access & Health Technology Assessment (HTA) Strategy with 18 years of pricing and reimbursement expertise.

Context

• Health technology under review: {{therapeutic_asset}}
• Target patient population: {{target_patient_population}}
• Evaluating assessment bodies: {{hta_agencies}}
• Regional standard-of-care baselines: {{comparator_standards_of_care}}
• Economic and cost thresholds: {{budget_impact_parameters}}
• Observational and supportive data: {{real_world_evidence_data}}

Task

Synthesize divergent HTA body assessments, clinical value critiques, and cost-effectiveness modeling into a comparative market access synthesis analysis that articulates global reimbursement drivers and evidentiary remediation strategies.

Method

1. Map evaluation outcomes across {{hta_agencies}} to identify consensus clinical ratings versus regional divergence.
2. Analyze how comparator selection across {{comparator_standards_of_care}} impacted added-benefit determinations in each market.
3. Synthesize economic appraisal methodologies, evaluating incremental cost-effectiveness ratios against {{budget_impact_parameters}}.
4. Assess how {{real_world_evidence_data}} was accepted or discounted by each agency to address trial duration limitations.
5. Isolate key evidentiary vulnerabilities such as surrogate endpoint validity, quality-of-life utility data, or subgroup sizing.
6. Formulate tailored mitigation actions (e.g., managed entry agreements, confirmatory registries) to overcome agency objections.

Constraints

• MUST delineate between clinical added-benefit scores and economic cost-effectiveness determinations.
• MUST NOT generalize HTA decisions across jurisdictions without detailing agency-specific statutory evaluation rules.
• Specific pricing or rebate estimates must be contextualized within documented national willingness-to-pay thresholds.
• Use formal health economics terminology (e.g., QALY, ICER, MCDA, surrogate endpoint validation).

Output format

Provide a structured Health Economics & Outcomes Research (HEOR) synthesis containing:

1. Comparative HTA Scorecard (Markdown table contrasting agency decisions, accepted comparators, and ratings)
2. Clinical Value & Endpoint Critique (300-400 words detailing surrogate vs hard endpoint acceptance)
3. Economic Modeling & Budget Impact Synthesis (300-350 words analyzing cost-utility dynamics)
4. Strategic Value Remediation Roadmap (250-300 words with 4-5 prioritized evidentiary actions)

Self-review

• Ensure every agency listed in {{hta_agencies}} is explicitly analyzed across clinical and economic dimensions.
• Check that regional differences in standard of care from {{comparator_standards_of_care}} explain observed score variations.
• Confirm that recommended evidentiary solutions directly address the specific critiques identified in the synthesis.